PubRank

K Borner

Author PubWeight™ 64.02‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother 1985 4.07
2 Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother 1987 3.09
3 Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur J Clin Microbiol 1986 2.00
4 Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol 1985 1.86
5 Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000 1.80
6 Multicentre study of a new enzymatic method of cholesterol determination. J Clin Chem Clin Biochem 1984 1.77
7 [Correlation of thromboplastin times in dicumarol treated patients using various preparations of thrombokinase]. Z Klin Chem Klin Biochem 1970 1.53
8 Pharmacodynamics of fluoroquinolones. Clin Infect Dis 1998 1.42
9 Azithromycin--review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother 1996 1.40
10 Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. Antimicrob Agents Chemother 1983 1.39
11 Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. Scand J Infect Dis 2001 1.37
12 Comparative pharmacokinetics of apalcillin and piperacillin. Antimicrob Agents Chemother 1984 1.28
13 Comparative pharmacokinetics of new quinolones. Drugs 1987 1.22
14 Reliability of drug history in analgesic users. Lancet 1984 1.21
15 Determination of apalcillin and its metabolites in human body fluids by high-pressure liquid chromatography. Antimicrob Agents Chemother 1982 1.19
16 Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob Agents Chemother 1996 1.19
17 Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol 1989 1.12
18 [Congenital nonspherocytic hemolytic anemia, cataract and glucose-6-phosphate dehydrogenase deficiency]. Dtsch Med Wochenschr 1966 1.11
19 Determination of cefmenoxime in human body fluids by high-performance liquid chromatography. Eur J Clin Microbiol 1983 1.08
20 Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam. Antimicrob Agents Chemother 1983 1.03
21 Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers. J Antimicrob Chemother 1992 1.02
22 Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother 2000 1.01
23 Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother 1992 1.00
24 Biliary excretion and pharmacokinetics of cefoperazone in humans. J Antimicrob Chemother 1983 0.99
25 Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother 2001 0.99
26 Chondrotoxicity and toxicokinetics of sparfloxacin in juvenile rats. Antimicrob Agents Chemother 1998 0.99
27 Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers. Antimicrob Agents Chemother 1988 0.97
28 Liquid chromatographic determination of ciprofloxacin and some metabolites in human body fluids. J Clin Chem Clin Biochem 1986 0.97
29 Concentrations of ofloxacin in human bone and in cartilage. J Antimicrob Chemother 1990 0.92
30 Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. Antimicrob Agents Chemother 1994 0.92
31 Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection. Antimicrob Agents Chemother 1998 0.91
32 Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections. Antimicrob Agents Chemother 1987 0.90
33 Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation. Transplant Proc 2001 0.90
34 [Enzymatic determination of total cholesterol with the Greiner Selective Analyzer (GSA-II) (author's transl)]. J Clin Chem Clin Biochem 1977 0.89
35 Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. Antimicrob Agents Chemother 1997 0.88
36 Kinetic interactions between azlocillin, cefotaxime, and cefotaxime metabolites in normal and impaired renal function. Clin Pharmacol Ther 1984 0.88
37 Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci. Antimicrob Agents Chemother 1996 0.88
38 Comparative evaluation of enoxacin, ofloxacin, ampicillin, and chloramphenicol for treatment of experimental Haemophilus influenzae pneumonia. Antimicrob Agents Chemother 1987 0.88
39 Therapeutic aminoglycoside monitoring in renal failure patients. Ther Drug Monit 1987 0.87
40 Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. Eur Respir J 1997 0.86
41 Pharmacokinetics of FCE 22891, a new oral penem. Antimicrob Agents Chemother 1990 0.86
42 Pharmacokinetics of new oral cephalosporins, including a new carbacephem. Clin Infect Dis 1993 0.86
43 Quinolone pharmacokinetics and metabolism. J Antimicrob Chemother 1990 0.85
44 Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime. Antimicrob Agents Chemother 1993 0.85
45 Comparative pharmacokinetics of intravenous ofloxacin and ciprofloxacin. J Antimicrob Chemother 1988 0.83
46 Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. Chemotherapy 1985 0.83
47 Pharmacokinetics of ciprofloxacin in liver cirrhosis. Chemotherapy 1990 0.82
48 Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers. Antimicrob Agents Chemother 1992 0.81
49 Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in cirrhosis of the liver. Chemotherapy 1984 0.81
50 Prospective randomized clinical trials of new quinolones versus beta-lactam antibiotics in lower respiratory tract infections. Scand J Infect Dis Suppl 1990 0.80
51 A candidate reference method for determination of total protein in serum. II. Test for transferability. Clin Chem 1981 0.79
52 Comparative efficacies of ciprofloxacin, ampicillin and chloramphenicol in treatment of experimental Haemophilus influenzae pneumonia. J Antimicrob Chemother 1987 0.79
53 Surface-modified amikacin-liposomes: organ distribution and interaction with plasma proteins. J Drug Target 1998 0.78
54 [Biotransformation of selected gyrase inhibitors]. Infection 1986 0.78
55 Unique aspects of quinolone pharmacokinetics. Clin Pharmacokinet 1989 0.78
56 Cefotaxime levels in ventricular cerebrospinal fluid, determined by bioassay and by high-performance liquid chromatography. Chemotherapy 1983 0.77
57 Aminoglycoside dosage in hemodialysis patients. J Clin Pharmacol 1987 0.76
58 [Concentration of metronidazole in bones]. Aktuelle Traumatol 1988 0.76
59 [Concentration of ciprofloxacin in bone tissue]. Aktuelle Traumatol 1993 0.75
60 Comparative pharmacokinetics of dirithromycin and erythromycin in normal volunteers with special regard to accumulation in polymorphonuclear leukocytes and in saliva. Eur J Clin Pharmacol 1997 0.75
61 [Status of electronic data processing at the Steglitz hospital of the Free University]. Med Lab (Stuttg) 1973 0.75
62 A study of the penetration of temocillin in the cerebrospinal fluid. Drugs 1985 0.75
63 [Determination of penicillamine as penicillaminic acid by chromatography on anion exchange]. Hoppe Seylers Z Physiol Chem 1965 0.75
64 Multivariate analysis of aminoglycoside levels in hemodialysis patients. Chemotherapy 1989 0.75
65 Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients. Eur J Clin Pharmacol 1992 0.75
66 Dosage adjustment of antiinfective therapy in patients with renal impairment. Int J Clin Pharmacol Ther 1997 0.75
67 Serum bactericidal activity and kinetics of azlocillin and moxalactam after single and combined administration. J Antimicrob Chemother 1983 0.75
68 Elimination of cefmenoxime during continuous haemofiltration. Eur J Clin Pharmacol 1993 0.75
69 [Statistical quality control with bovine serum as test material]. Z Klin Chem Klin Biochem 1970 0.75
70 [Comparative studies of carboxylesterases (EC 3.1.1.1) from liver and kidney microsomes]. Hoppe Seylers Z Physiol Chem 1969 0.75
71 [A simple system for the documentation of laboratory findings on the example of a hospital information system]. Methods Inf Med 1973 0.75
72 [Statistical material in electronic processing of laboratory data]. Dtsch Med J 1971 0.75
73 Ciprofloxacin: a comparative evaluation of its bactericidal activity in human serum against four enterobacterial species. Drugs Exp Clin Res 1986 0.75
74 Practical experiences with bovine serum in quality control. Z Klin Chem Klin Biochem 1974 0.75
75 Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers. Clin Microbiol Infect 2003 0.75
76 Different mechanisms of TEM-1 and Oxa-1 mediated resistance to piperacillin in E. coli. Zentralbl Bakteriol Mikrobiol Hyg A 1984 0.75
77 Vancomycin dosing in haemodialysis patients and Bayesian estimate of individual pharmacokinetic parameters. Int J Artif Organs 1994 0.75
78 Renal elimination of sulfo-ciprofloxacin, a new metabolite of ciprofloxacin. Eur J Clin Microbiol 1986 0.75
79 Quinine dosage in severe malaria with renal failure necessitating haemodialysis. Eur J Clin Pharmacol 1989 0.75
80 [Follow-up study after psychomotor therapy]. Acta Paedopsychiatr 1978 0.75
81 Pharmacokinetics of ofloxacin and adequacy of maintenance dose for patients on haemodialysis. J Antimicrob Chemother 1990 0.75
82 Effects of a protein-free diet on amino acids and sex hormones of rats during the early postimplantation stages of pregnancy. J Reprod Fertil 1975 0.75
83 [Determination of digoxin in serum. Comparison of radioimmunoassay and a heterogeneous enzyme immunoassay (author's transl)]. J Clin Chem Clin Biochem 1978 0.75
84 Efficacy of sustained release theophylline given at three different evening intake times in addition to a baseline medication. Eur Respir J 1990 0.75
85 [Colorimetric calibration of micropipettes]. Z Klin Chem Klin Biochem 1967 0.75
86 Penetration of ciprofloxacin into the spinal fluid in patients with viral and bacterial meningitis. Arzneimittelforschung 1990 0.75
87 [Installation of an electronic computer in the central laboratory of cliniacl chemistry]. Z Klin Chem Klin Biochem 1968 0.75
88 [Standardization of the Quick test. Reference thromboplastin of reference plasma?]. Blut 1974 0.75
89 Biliary elimination of apalcillin in cholecystectomized patients. Chemotherapy 1985 0.75
90 Comparative pharmacokinetics of glycopeptide antibiotics, and the influence of teicoplanin on granulocyte function. Scand J Infect Dis Suppl 1990 0.75
91 [Efficacy of a theophylline retard preparation administered at 3 different intake times additionally to basic medication]. Pneumologie 1991 0.75
92 Multiple-dose-kinetics of ofloxacin after intraperitoneal application in CAPD patients. Perit Dial Int 1991 0.75
93 The influence of intravenous canrenoate on the determination of digoxin in serum by radio- and enzyme-immunoassay. Int J Clin Pharmacol Biopharm 1979 0.75
94 Chrono-optimization of the time of evening administration with unequally divided twice-daily theophylline. Chronobiol Int 1987 0.75
95 [The Greiner Selective Analyzer. II. Status of the development of a clinical-chemical autoanalyzer (proceedings)]. J Clin Chem Clin Biochem 1977 0.75
96 [Growth increase of a permanent tissue culture cell line cultivated in a lactalbumin-yeast-medium reached by additional supply with nutritive material]. Zentralbl Bakteriol Orig A 1971 0.75
97 Metronidazole kinetics and liver function in hepatic cirrhosis. Chemioterapia 1987 0.75
98 Use of fluoroquinolones in lower respiratory tract infections (LRTI). Int J Antimicrob Agents 1994 0.75
99 [Determination of triiodothyronine in serum with a heterologous enzyme immunoassay: results of a group survey]. J Clin Chem Clin Biochem 1981 0.75
100 [Candidate selected method for the enzymatic determination of total cholesterol in serum]. J Clin Chem Clin Biochem 1983 0.75
101 [A new absolute coulometer for the determination of chloride (author's transl)]. Z Klin Chem Klin Biochem 1972 0.75
102 [Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses]. Med Welt 1983 0.75
103 Cefotiam during continuous haemofiltration. Eur J Clin Pharmacol 1993 0.75
104 [Determination of thyroxine in serum by a heterogeneous enzyme immunoassay: results of a joint trial]. J Clin Chem Clin Biochem 1979 0.75
105 [Electronic data recording in the clinical chemistry laboratory]. Z Klin Chem Klin Biochem 1969 0.75
106 [Metronidazole-resistant trichomoniasis and successful therapy following high dosage]. Hautarzt 1988 0.75
107 Combination effects of ciprofloxacin, clindamycin, and metronidazole intravenously in volunteers. Am J Med 1989 0.75
108 [Current aspects of pseudomonas meningitis]. Neurochirurgia (Stuttg) 1985 0.75
109 Comparative pharmacokinetics of the new oral cephalosporins. Drugs 1994 0.75
110 Ciprofloxacin intravenous dose variance. Am J Med 1989 0.75